波形蛋白(VIM)多克隆抗体

Polyclonal Antibody to Vimentin (VIM)

  • 波形蛋白(VIM)多克隆抗体产品包装(模拟)
  • 波形蛋白(VIM)多克隆抗体产品包装(模拟)
  • Certificate通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对VIM的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别VIM。

用法

Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

赠品

相关产品

编号适用物种:Sus scrofa; Porcine (Pig,猪)应用(仅供研究使用,不用于临床诊断!)
PAB040Po01波形蛋白(VIM)多克隆抗体WB; IHC; ICC; IP.

参考文献

杂志参考文献
Cancer Epidemiology, Biomarkers & PreventionAberrant Vimentin Methylation Is Characteristic of Breast Cancer[pubmed:22315367]
Scientific ReportsGlyoxalase 1-knockdown in human aortic endothelial cells - effect on the proteome andendothelial function estimates.[pubmed:27898103]
Journal of ProteomicsHtrA3 is a cellular partner of cytoskeleton proteins and TCP1α chaperonin[Pubmed:29477555]
Journal of Biological ChemistryGrowth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy[Pubmed: 31511328]
American Journal of TransplantationExtracellular vesicles derived from injured vascular tissue promote the formation of tertiary lymphoid structures in vascular allografts[Pubmed: 31729155]
LungIs Vimentin the Cause or Effect of Obstructive Sleep Apnea Development?[Pubmed: 32088750]
Cell Biol ToxicolZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer[33566221]
CELL BIOLOGY AND TOXICOLOGYMetastatic suppression by DOC2B is mediated by inhibition of epithelial-mesenchymal transition and induction of senescence[33758996]
Comparison of Vimentin Levels Between Preeclamptic and Normotensive Pregnant Women[]
Advanced glycation end-products associate with podocytopathy in type II diabetic patients[]
Non-POU Domain-Containing Octamer-Binding (NONO) Protein Stability Regulated by PIN1 is Crucial for Breast Cancer Tumorigenicity Via the MAPK/β …[]